FCFS

160.03

-0.63%↓

RPT.US

2.42

+0.83%↑

FCFS

160.03

-0.63%↓

RPT.US

2.42

+0.83%↑

FCFS

160.03

-0.63%↓

RPT.US

2.42

+0.83%↑

FCFS

160.03

-0.63%↓

RPT.US

2.42

+0.83%↑

FCFS

160.03

-0.63%↓

RPT.US

2.42

+0.83%↑

Search

Sartorius Stedim Biotech.

Chiusa

SettoreFinanza

188.3 -0.29

Panoramica

Variazione del prezzo dell'azione

24h

Corrente

Minimo

187.3

Massimo

191

Metriche Chiave

By Trading Economics

Entrata

-23M

93M

Vendite

400K

745M

P/E

Media del settore

73.948

26.975

EPS

0.94

Margine di Profitto

12.43

Dipendenti

10,134

EBITDA

-55M

201M

Raccomandazioni

By TipRanks

Raccomandazioni

Acquista

Previsioni per 12 mesi

+20.05% upside

Statistiche di mercato

By TradingEconomics

Capitalizzazione di Mercato

-354M

19B

Apertura precedente

188.59

Chiusura precedente

188.3

Notizie sul Sentiment di mercato

By Acuity

17%

83%

17 / 528 Classifica in Finance

Punteggio Tecnico

By Trading Central

Fiducia

Bullish Evidence

Sartorius Stedim Biotech. Grafico

Le prestazioni passate non sono un indicatore affidabile dei risultati futuri.

Notizie correlate

7 nov 2025, 21:06 UTC

I principali Market Mover

JBS Down After Trump Calls for Probe into Meat-Packing Companies

7 nov 2025, 22:36 UTC

Utili

McDonald's Stock Challenged By a Tougher Economy, Analyst Says. Plus, Marriott, Snowflake, and More. -- Barrons.com

7 nov 2025, 22:22 UTC

Utili

The Score: GM, Tesla, Palantir, American Airlines and More Stocks That Defined the Week -- WSJ

7 nov 2025, 22:03 UTC

Utili

Constellation Software 3Q Rev $2.95B >CSU.T

7 nov 2025, 22:03 UTC

Utili

Constellation Software 3Q Net $210M >CSU.T

7 nov 2025, 22:03 UTC

Utili

Constellation Software 3Q EPS $9.89 >CSU.T

7 nov 2025, 21:50 UTC

Discorsi di Mercato

Financial Services Roundup: Market Talk

7 nov 2025, 21:50 UTC

Discorsi di Mercato

Health Care Roundup: Market Talk

7 nov 2025, 20:59 UTC

Utili

Palantir's CEO Says His Earnings Were the Best Ever. They Weren't Even the Best of the Week. -- Barrons.com

7 nov 2025, 20:26 UTC

Discorsi di Mercato

Natural U.S. Gas Futures Extend Rally to Three Weeks -- Market Talk

7 nov 2025, 20:22 UTC

Utili

Free-Spending Big Tech Dominates Earnings. As for the Rest: Don't Miss. -- Barrons.com

7 nov 2025, 20:04 UTC

Discorsi di Mercato

Oil Futures Close Choppy Week With Losses -- Market Talk

7 nov 2025, 19:34 UTC

Discorsi di Mercato

Gold Posts Small Gain for Week -- Market Talk

7 nov 2025, 19:31 UTC

Discorsi di Mercato
Acquisizioni, Fusioni, Takeovers

Prices of Gas-Fired Power Plants Have Room to Grow -- Market Talk

7 nov 2025, 19:17 UTC

Utili

These Stocks Are Moving the Most Today: Tesla, Expedia, Take-Two, Block, Affirm, Sunrun, Globus Medical, JFrog, and More -- Barrons.com

7 nov 2025, 19:09 UTC

Utili

Wendy's Turnaround Won't Be Easy. Earnings, and the Stock, Tell the Story. -- Barrons.com

7 nov 2025, 19:08 UTC

Utili

KKR Defied Private-Equity Fundraising Slump in the Third Quarter -- WSJ

7 nov 2025, 18:31 UTC

Discorsi di Mercato

U.S. Oil RIg Count Unchanged at 414 -- Market Talk

7 nov 2025, 17:27 UTC

Discorsi di Mercato

EPA Announces New Exemptions to Biofuel Blending Rules -- Market Talk

7 nov 2025, 17:20 UTC

Discorsi di Mercato

Eli Lilly GLP-1 Deal with Trump Administration Provides Net Boost -- Market Talk

7 nov 2025, 17:20 UTC

Discorsi di Mercato

Tech, Media & Telecom Roundup: Market Talk

7 nov 2025, 17:20 UTC

Discorsi di Mercato

Financial Services Roundup: Market Talk

7 nov 2025, 17:20 UTC

Discorsi di Mercato

Health Care Roundup: Market Talk

7 nov 2025, 17:17 UTC

Acquisizioni, Fusioni, Takeovers

Satair Expects to Complete Purchase in Early 2026

7 nov 2025, 17:17 UTC

Acquisizioni, Fusioni, Takeovers

Satair: Deal Includes Unical's and ecube's Seven Operational Sites and Offices, With Combined 2024 Rev of $298M and Headcount of 413

7 nov 2025, 17:15 UTC

Acquisizioni, Fusioni, Takeovers

Airbus Unit Satair to Buy Unical Aviation From Platinum Equity

7 nov 2025, 17:09 UTC

Discorsi di Mercato

PENN Is Falling Further Behind Competitors -- Market Talk

7 nov 2025, 16:49 UTC

Discorsi di Mercato

Losing ESPN Partnership Will Hurt PENN -- Market Talk

7 nov 2025, 16:24 UTC

Discorsi di Mercato

OPEC+'s Output Hike Pause Comes Amid Excess Supply, Lower Spare Capacity -- Market Talk

7 nov 2025, 16:17 UTC

Discorsi di Mercato

Oil Market Faces Oversupply But "Glut" Might Be Overblown -- Market Talk

Confronto tra pari

Modifica del prezzo

Sartorius Stedim Biotech. Previsione

Obiettivo di Prezzo

By TipRanks

20.05% in crescita

Previsioni per 12 mesi

Media 228.57 EUR  20.05%

Alto 246 EUR

Basso 210 EUR

Basato su 7 analisti di Wall Street che offrono Obiettivi di Prezzo a 12 mesi per Sartorius Stedim Biotech. - Dist negli ultimi 3 mesi.

Consenso sulla valutazione

By TipRanks

Acquista

7 ratings

5

Acquista

2

Mantieni

0

Vendi

Punteggio Tecnico

By Trading Central

202.7 / 211.7Supporto e resistenza

A breve termine

Bullish Evidence

A termine intermedio

Strong Bullish Evidence

A lungo termine

Strong Bullish Evidence

Sentiment

By Acuity

17 / 528 Classifica in Finanza

Notizie sul Sentiment di mercato

Prove rialziste molto forti

Volatilità

Sotto la media

Volume delle notizie (RCV)

Sopra la media

Notizie finanziarie

Spese di vendita e di amministrazione

Spese operative

Utile prima delle imposte

Vendite

Costo delle vendite

Utile lordo sulle vendite

Interessi passivi sul debito

EBITDA

Utile operativo

$

Chi Siamo Sartorius Stedim Biotech.

Sartorius Stedim Biotech S.A. engages in the production and sale of instruments and consumables for the biopharmaceutical industry worldwide. The company offers various products, such as cell lines; cell culture media; bioreactors; advanced therapies; and a range of products for separation, purification, and concentration processes, as well as products and systems for storage and transportation of intermediate and finished biological products. It also provides cell cultivation, fermentation, separation, purification, and fluid management services; biolayer interferometry instruments; microbiology enumeration, sterility testing, and air monitoring instruments; pipette products; sensors and analyzers; biomolecule analysis tools; flow cytometry; batch and intensified chromatography systems; lab data and fleet management software; live cell imaging and analysis; surface plasmon resonance solutions; and weighing products. In addition, the company offers data analytics software for modeling and optimizing processes of biopharmaceutical development and production; process automation platform and software; and develops and produces transfection, as well as other DNA/RNA delivery reagents and plasmid DNA. It serves manufacturers of medications, vaccines, foods, and chemicals, as well as research and development laboratories. The company was incorporated in 1978 and is headquartered in Aubagne, France. As of December 31, 2023, Sartorius Stedim Biotech S.A. operates as a subsidiary of Sartorius AG.
help-icon Live chat